Supplementary Table 1 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

<p>Supplementary Table 1. Patterns of PD-L1 staining at various time points of MAPK inhibitor treatment (n=55 PD-L1 positive patients).</p>